Europe Genetic Testing Market Size, Trends & Growth Opportunity, By Type (Carrier Testing, Diagnostic Testing, New-born Screening, Predictive & Presymptomatic Testing, Prenatal Testing, and Others), By Disease (Alzheimer's Disease, Cancer , Cystic Fibrosis, Sickle Cell Anaemia, Duchenne Muscular Dystrophy, Thalassemia , Huntington's Disease, and Others), and By Technology (Cytogenetic Testing, Biochemical Testing, and Molecular Testing), By Region and Forecast Till 2027.
Europe Genetic Testing Market
Europe Genetic Testing Market was valued at US$ 2,472.0 million in 2021 and it is projected to reach at US$ 4,262.4 million by 2027, at a CAGR of 9.51% during the forecast period. 
The prevalence of genetic, infectious, and chronic diseases is rising, genetic sequencing is becoming more affordable, and more people are turning to precision medicine diagnostic techniques. Genetic tests are medical procedures that search for changes in proteins, genes, or chromosomes. The findings of the test can confirm a suspected underlying genetic condition or help determine a person's risk of developing or passing on a genetic disease.
Market Drivers
One of the main factors propelling the market for genetic testing is the rising frequency of genetic disorders in Europe. A useful tool for identifying genetic abnormalities and enhancing patient outcomes is genetic testing. The demand for genetic testing services has increased as a result of the ongoing technological improvements in genetic testing that have made testing more convenient and economical.
Market Restraints
Because genetic testing is frequently expensive, many people may not be able to afford it. This can limit market expansion. The adoption of genetic testing may be constrained by the ethical and legal issues it brings, such as privacy, discrimination, and genetic alteration.
Market Segmentation
The Europe Genetic Testing Market is segmented into type such as carrier testing, diagnostic testing, new-born screening, predictive & presymptomatic testing, prenatal testing, and others. On the basis of disease, market is segmented into alzheimer's disease, cancer , cystic fibrosis, sickle cell anaemia, Duchenne muscular dystrophy, thalassemia , Huntington’s disease, and others. Further, market is segmented into technology such as cytogenetic testing, biochemical testing, and molecular testing.
Country Analysis
The United Kingdom is one of the largest genetic testing markets in Europe, driven by its advanced healthcare infrastructure and significant government funding for genetic testing research.
Market Key Players
Various key players are listed in this report such as Abbott Laboratories, Illumina Inc., Eurofins Scientific, Qiagen, Elitech Group, Thermo Fischer Scientific, Centogene AG, Blueprint Genetics, 23andMe Inc., F. Hoffmann-La Roche Ltd, etc.
Market Taxonomy
By Type
• Carrier Testing
• Diagnostic Testing
• New-born Screening
• Predictive & Presymptomatic Testing
• Prenatal Testing
• Others
By Disease 
• Alzheimer's Disease
• Cancer 
• Cystic Fibrosis
• Sickle Cell Anaemia
• Duchenne Muscular Dystrophy
• Thalassemia 
• Huntington's Disease
• Others
By Technology
• Cytogenetic Testing
• Biochemical Testing
• Molecular Testing
By Country
• Germany
• UK
• France
• Turkey
• Switzerland
• Norway
• Sweden
• Spain
• Italy
• Denmark
• Finland
• Iceland
• Poland
• Luxembourg
• Netherlands
• Belgium

Europe Genetic Testing Market 
1 Introduction
1.1 Objective of the Study
1.2 Market definition
1.3 Market Scope
2 Research Methodology
2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Diseases
3 Executive Summary
4 Europe Genetic Testing Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 Europe Genetic Testing Market, By Type
5.1 Y-o-Y Growth Comparison, By Type 
5.2 Europe Genetic Testing Market Share Analysis, By Type 
5.3 Europe Genetic Testing Market Size and Forecast, By Type
5.3.1. Carrier Testing
5.3.2. Diagnostic Testing
5.3.3. Newborn Screening
5.3.4. Predictive & Presymptomatic Testing
5.3.5. Prenatal Testing
5.3.6.Others
6  Global  Testing, Inspection, and Certification Market , By Disease
6.1 Y-o-Y Growth Comparison, By Disease
6.2 Europe Genetic Testing Market Share Analysis, By Disease
6.3 Europe Genetic Testing Market Size and Forecast, By Disease
6.3.1. Alzheimer's Disease
6.3.2. Cancer 
6.3.3.Cystic Fibrosis
6.3.4. Sickle Cell Anemia
6.3.5. Duchenne Muscular Dystrophy
6.3.6. Thalassemia 
6.3.7. Huntington’s Disease
6.3.8. Others  
7 Europe Genetic Testing Market, By Technology
7.1 Y-o-Y Growth Comparison, By Technology
7.2 Europe Genetic Testing Market Share Analysis, By Technology
7.3 Europe Genetic Testing Market Size and Forecast, By Technology
7.3. 1 Cytogenetic Testing
7.3.2 .Biochemical Testing
7.3.3. Molecular Testing
8 Testing, Inspection, and Certification Market, By Region
8.1 Testing, Inspection, and Certification Market Share Analysis, By Europe
8.2 Testing, Inspection, and Certification Market Share Analysis, By Europe
8.3 Testing, Inspection, and Certification Market Size and Forecast, By EUROPE
9Europe Genetic Testing Market Analysis and Forecast (2022 – 2027)
9.1 Introduction
9.2 Europe Genetic Testing Market Share Analysis, By Type 
9.3 Europe Genetic Testing Market Size and Forecast, By Disease 
9.4 Europe Genetic Testing Market Size and Forecast, By Technology
9.5 Europe Genetic Testing Market Size and Forecast, By Country
9.5.1 Germany 
9.5.2 UK
9.5.3 France
9.5.4. Turkey
9.5.5Switerland
9.5.6Norway
9.5.7Sweden
9.5.8Spain
9.5.9Italy
9.5.10Denmark
9.5.11Finland
9.5.12 Iceland
9.5.13Poland
9.5.14 Luxembourg
9.5.15 Netherlands
9.5.17Belguim
10Competitive Analysis
10.1 Competition Dashboard
10.2 Market share Analysis of Top Vendors
10.3 Key Development Strategies
11Company Profiles
11.1 Abbott Laboratories
11.1.1 Overview
11.1.2 Offerings
11.1.3 Key Financials
11.1.4 Business Segment & Geographic Overview
11.1.5 Key Market Developments
11.1.6 Key Strategies
11.2 Illumina Inc 
11.2.1 Overview
11.2.2 Offerings
11.2.3 Key Financials
11.2.4 Business Segment & Geographic Overview
11.2.5 Key Market Developments
11.2.6 Key Strategies
11.3 Eurofins Scientific
11.3.1 Overview
11.3.2 Offerings
11.3.3 Key Financials
11.3.4 Business Segment & Geographic Overview
11.3.5 Key Market Developments
11.3.6 Key Strategies
11.4 Qiagen
11.4.1 Overview
11.4.2 Offerings
11.4.3 Key Financials
11.4.4 Business Segment & Geographic Overview
11.4.5 Key Market Developments
11.4.6 Key Strategies
11.5 Elitech Group 
11.5.1 Overview
11.5.2 Offerings
11.5.3 Key Financials
11.5.4 Business Segment & Geographic Overview
11.5.5 Key Market Developments
11.5.6 Key Strategies
11.6   Centogene AG
11.6.1 Overview
11.6.2 Offerings
11.6.3 Key Financials
11.6.4 Business Segment & Geographic Overview
11.6.5 Key Market Developments
11.6.6 Key Strategies
11.7 Blueprint Genetics
11.7.1 Overview
11.7.2 Offerings
11.7.3 Key Financials
11.7.4 Business Segment & Geographic Overview
11.7.5 Key Market Developments
11.7.6 Key Strategies 
11.8 23andMe Inc
11.8.1 Overview
11.8.2 Offerings
11.8.3 Key Financials
11.8.4 Business Segment & Geographic Overview
11.8.5 Key Market Developments
11.8.6 Key Strategies 
11.9 F. Hoffmann-La Roche Ltd
11.9.1 Overview
11.9.2 Offerings
11.9.3 Key Financials
11.9.4 Business Segment & Geographic Overview
11.9.5 Key Market Developments
11.9.6 Key Strategies 
11.10 Thermo Fischer Scientific
11.10.1 Overview
11.10.2 Offerings
11.10.3 Key Financials
11.10.4 Business Segment & Geographic Overview
11.10.5 Key Market Developments
11.10.6 Key Strategies